MarginsXMarginsX
Home › Markets › Health Care › EPRX

Eupraxia Pharmaceuticals Inc. (EPRX)

EPRX trades on Nasdaq in Health Care, Pharmaceuticals and Biotechnology. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.34
-9.94% on the day
Market cap
$493.6M
Small cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$38.6M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 40-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1581178/000119312526104765/0001193125-26-104765-index.htm. Net income: SEC 40-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerEPRX on Nasdaq
SectorHealth Care
IndustryPharmaceuticals and Biotechnology
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001581178
SEC industry codePharmaceutical Preparations
Incorporated inBC
Canadian listingTSX: EPRX

Financials · 2025

LineValue
Revenue$0
Net income-$38.6M
Operating incomeNot in SEC XBRL data
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$80.6M
Total assets$86.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
33.9 months
$80.6M cash at December 31, 2025
Share count, 1 year
+45.7%
2024-12-31 to 2025-12-31
Going-concern doubt
No
40-F filed March 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.40-F 2026-03-13
Cash and burn$80.6M cash; operating cash flow -$7.1M a quarter.Report 2025-12-31
Shares outstanding51,939,206 (2025-12-31); 35,641,603 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Vancouver, CanadaPCAOB Form AP 2026-04-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$0-$38.6M-$28.6M$80.6M$0$040-F 2026-03-13
FY 2024
2024-12-31
$0-$25.5M-$30.0M$33.1M$0$040-F 2025-03-20
FY 2023
2023-12-31
$0-$28.2M-$20.7M$19.3M$10.5M$040-F 2024-04-01
FY 2022
2022-12-31
Not filed-$18.5M-$14.4M$18.3M$63KNeeds four quarters40-F 2024-04-01

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report40-F2026-03-13
Latest quarterly / interim6-K2026-11-10

Source: SEC EDGAR submissions feed, 132 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+18.3%
1 month+22.0%
3 months+22.2%
Year to date+7.9%
1 year+28.5%
From 52-week high-10.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Pharmaceuticals and Biotechnology

No other listed companies with a market cap share this industry.

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier